ProQR Therapeutics (PRQR) Receivables - Other (2021 - 2025)

ProQR Therapeutics' Receivables - Other history spans 4 years, with the latest figure at $892277.2 for Q4 2024.

  • For Q4 2024, Receivables - Other rose 11.32% year-over-year to $892277.2; the TTM value through Dec 2024 reached $892277.2, up 11.32%, while the annual FY2024 figure was $903752.5, 12.14% up from the prior year.
  • Receivables - Other for Q4 2024 was $892277.2 at ProQR Therapeutics, up from $801575.2 in the prior quarter.
  • Across five years, Receivables - Other topped out at $892277.2 in Q4 2024 and bottomed at $306584.2 in Q4 2021.
  • The 4-year median for Receivables - Other is $592084.0 (2023), against an average of $595757.3.
  • The largest annual shift saw Receivables - Other surged 109.51% in 2023 before it increased 11.32% in 2024.
  • A 4-year view of Receivables - Other shows it stood at $306584.2 in 2021, then increased by 24.79% to $382592.8 in 2022, then soared by 109.51% to $801575.2 in 2023, then rose by 11.32% to $892277.2 in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Receivables - Other are $892277.2 (Q4 2024), $801575.2 (Q4 2023), and $382592.8 (Q4 2022).